Jump to content

LaurenH

Administrators
  • Content count

    350
  • Joined

  • Last visited

  • Days Won

    12

LaurenH last won the day on June 24

LaurenH had the most liked content!

About LaurenH

  • Rank
    MODERATOR
  • Birthday 10/18/1985

Profile Information

  • Gender
    Female
  • US State
    MARYLAND
  • Status
    No
  • Interests
    Social Media, Running, Yoga, Reading, Traveling, Cooking

Recent Profile Visitors

1,373 profile views
  1. Here is the weekly clip report: Health “The Difference Between Small Cell and Non-Small Cell Lung Cancer” http://www.health.com/smoking/small-cell-lung-cancer-non-small-cell-lung-cancer Genetic Engineering & Biotechnology News “CRISPR Screen Identifies Top 100 Essential Genes for Cancer Immunotherapy” http://www.genengnews.com/gen-news-highlights/crispr-screen-identifies-top-100-essential-genes-for-cancer-immunotherapy/81254771 Healio “FDA Grants Orphan Drug Designation to Tesevatinib for EGFR-Mutated Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{1be8c744-6be6-42fa-b024-6e12a8bd01f5}/fda-grants-orphan-drug-designation-to-tesevatinib-for-egfr--mutated-non-small-cell-lung-cancer Targeted Oncology “Combinations, Biomarkers Will Be Future Focus in Metastatic NSCLC, Expert Says” http://www.targetedonc.com/news/combinations-biomarkers-will-be-future-focus-in-metastatic-nsclc-expert-says Onc Live “Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC” http://www.onclive.com/web-exclusives/sequencing-switches-intriguing-combos-being-debated-in-alk-nsclc U.S. News & World Report “Best Hospitals for Cancer” http://health.usnews.com/best-hospitals/rankings/cancer Health “7 Causes of Lung Cancer in Non-Smokers” http://www.health.com/smoking/causes-of-lung-cancer-non-smoker MIT Technology Review “Cancer Blood Tests Score Early Success” https://www.technologyreview.com/s/608601/cancer-blood-tests-score-early-success/ Cure “Expert Discusses Stem Cell Research and Personalizing Lung Cancer Care” http://www.curetoday.com/articles/expert-discusses-stem-cell-research-and-personalizing-lung-cancer-care OncLive “Molecular Targets Could Be Unraveled for Patients with Non-Driver NSCLC” http://www.onclive.com/web-exclusives/molecular-targets-could-be-unraveled-for-patients-with-nondriver-nsclc OncLive “Liquid Biopsies, NGS Expected to Become Standard in Lung Cancer” http://www.onclive.com/web-exclusives/liquid-biopsies-ngs-expected-to-become-standard-in-lung-cancer
  2. New here

    Hi, Daughter74, Welcome to LCSC. I am sorry to hear about your dad's diagnosis. I am glad that you've found this community. This is a great place to connect with others whose lives have been impacted by lung cancer. LUNGevity's Lung Cancer 101 website has a lot of information about small cell lung cancer (SCLC). We also offer support services and resources for survivors and caregivers. Please let me know if you'd like more information about any of LUNGevity's resources and programs and I will be happy to help. We are here for you! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  3. Allyn Drew

    Hi, Allyn, Welcome to LCSC. I am sorry to hear about your wife's diagnosis. You have come to a good place to connect with other caregivers and lung cancer survivors. Our members have a wealth of experience navigating a lung cancer diagnosis and treatment. If you're comfortable, could you tell us a bit more about your wife's diagnosis? Then we may be able to connect you with someone who has a similar diagnosis. We are here for you. With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  4. New

    Hi, Kimi, Welcome to LCSC. I hope that you will find both hope and help as you connect with our members. Here is a post about how to use this site. Please let us know if you have any questions! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  5. Introducing myself

    Hi, ViviAnn, Thank you for making an introductory post! Welcome to LCSC. I'm glad to see you've been able to connect with Susan. Please continue to join in the conversations in the discussion boards and feel free to post questions. If you'd like more information about LUNGevity's support resources and programs, I would be happy to connect with you. With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  6. Surgery 3/27/17 for stage IIb nsclc

    Hi, Karen, Welcome to LCSC. I'm glad to see you've already connected with some of our members. This is a great community to find hope and help while navigating a lung cancer diagnosis and treatment. Here is a link to an overview on how to use the site. Please continue to explore the discussion boards, read the blogs, and join the conversations which resonate with you. Feel free to ask questions and please let me know if you'd like additional information about LUNGevity's resources and support programs. We are here for you! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  7. Hi, Lori, Welcome to LCSC. We are glad you've joined this community. I hope that here, like in the ALKies group, you can make many meaningful connections and find both hope and helpful information. Please feel free to explore the discussion boards and join in on the conversations. We also have member blogs that you can check out. I would be happy to provide you with educational resources or information about LUNGevity's support programs, should you desire them. Please continue to post updates. We are here for you! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  8. For many cancer patients genomic testing provides a unique opportunity to identify the most promising drug therapy options based on genetic indicators identified through the test results. Patient Advocate Foundation (PAF) is pleased to offer theGenomic Testing Support CareLine which is designed to provide assistance to patients who have completed a genomic test on clinical samples collected during their cancer or other genomics-guided diagnosis, or who are encountering barriers accessing and finalizing that process. Patients who are having trouble accessing treatment that has been identified by the testing are also able to receive assistance to reduce some of the financial or insurance barriers that may exist. The CareLine is staffed by expert case managers who offer high touch, personalized assistance to patients, caregivers and providers who are utilizing genomic tests to aid in treatment decisions, helping with both the denial of drugs with indicators based on test results and the denial of any genomic test regardless of cancer type. This represents a comprehensive approach to patient support and allows PAF to actively engage in the delivery of appeals assistance from the initial genomic testing phase through the actual delivery of prescribed care. Those in need of assistance can reach the Genomic Testing Support CareLine toll free at (866) 460-1928 or through the web based portal at genomicsupport.pafcareline.org. From diagnosis to survivorship, this free service is here for patients and their families as they navigate treatment and healthcare based on genomic testing. Genomic Testing Support CareLine Details: Two ways to initiate a request for support: phone and online secure portal No financial requirements to qualify for assistance and all services are free of charge for patients and their families Assistance for patients who have already undergone genomic testing/profiling and now wish to proceed with accessing an off label drug Assistance with insurance challenges relative to accessing the prescribed genomic test Assistance with clinical trials research and access Assistance with prior authorization or predetermination requests “Each cancer journey is unique and PAF is grateful to have an opportunity to offer this exciting new program that adds a unique layer of personalized support to complement the care that patients are receiving from their doctors and treatment teams each day,” says Beth Moore, Executive Vice President of the Patient Advocate Foundation. PAF case managers are on call to answer questions and provide direct assistance to cancer patients facing challenges accessing genomic testing and/or prescribed care based on test results. The Genomic Testing Support CareLine can be accessed toll free at (866) 460-1928 or by visiting genomicsupport.pafcareline.org. Expanded Assistance Now Available for Cancer Patients Seeking Access to Genomic Testing and Drug Therapies through Patient Advocate Foundation’s Genomic Testing Support CareLine.docx
  9. IASLC CHICAGO MULTIDISCIPLINARY SYMPOSIUM IN THORACIC ONCOLOGY September 22 - 24 2016 | Chicago, Illinois | Contact: Pia.Hirsch@iaslc.org Marriott Downtown Magnificent Mile For more information, or to register online, visit the event website. 251XXX_2017_Chicago_PROOF.pdf
  10. Hi I'm new to this site

    Hi, vinnpal, Welcome to LCSC. I am glad you've been able to connect with several of our members and that their posts have given you some of the information you need. Here is a link to LUNGevity's website where you can find more questions to ask your medical team. I am happy to provide you with additional resources or more information about LUNGevity's support programs. In the meantime, please continue to explore the discussion boards, join the conversations, and ask questions. We are here for you! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  11. Update...Praying for NED

    So glad to hear it! Thank you for the update! I hope his follow up appointments go well. We'll be thinking of you and your family. Please keep us posted! Lauren -- Digital Community Manager LUNGevity Foundation
  12. So much so fast...

    Hi, Sherry, Welcome to LCSC. I'm sorry you've been through so much lately. We're glad that you found this community. It is a great place to connect with others who are navigating a lung cancer diagnosis and to share experiences. Please feel free to explore the discussion boards and join in on any of the conversations which resonate with you. When you have more information about your diagnosis, this community is a good place to ask questions. I am also happy to give you some information on LUNGevity's support programs. In the meantime, know that we are here for you! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  13. Study of Lifestyle and Quality of Life in Cancer

    Thank you both for providing us with that feedback! We want to make sure people have a realistic idea of how long the study will take. Lauren -- Digital Community Manager LUNGevity Founation
  14. Learning to accept

    Whether you walk/run across the finish line, it still counts! Good luck with your training! Keep us posted! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  15. Co-written by LUNGevity and Mesothelioma Cancer Alliance A recent shift in cancer treatments from traditional, aggressive, overarching methods to targeted therapies tailored to individual patients and their medical situation has produced a resurgence of research in immunotherapy as a cancer treatment including multiple FDA approvals in the last few years. Today we are it taking a moment to reflect on how immunotherapy has progressed over the last twenty years. Immunotherapy is nothing new and has been in use for more than a century, but its potential is often seen as a mystery. While the average person might not understand the finer intricacies of these rapidly developing treatments, patients and doctors alike are reaping the benefits. Immunotherapy is a type of treatment that is meant to boost the body’s own immune system to help identify and fight rogue pathogens and cells, including cancer cells. In some cases, treatments can help activate the body’s defenses to better equip a patient to fight off diseases more efficiently. In other instances, immunotherapy may provide the immune system with proteins it’s lacking. When cancer cells develop, they may send signals like a mask that deceives the patient’s body into recognizing them as normal, so the invading cells aren’t attacked. In other cases, a person’s immune system might notice the cancer cells are different, but still doesn’t attack them. To help combat this, medical researchers have developed drugs called immune checkpoint inhibitors to provide T cells—specialized immune cells—the ability to identify cancer cells and attack them. For example, cancer cells produce high amounts of a protein called PD-L1. This protein binds to T cells and blocks them from launching an attack against the cancer cells Immune checkpoint inhibitors that can block this connection have helped patients fight several types of cancer, including melanoma, some types of lung cancer, and head and neck cancers. Therapeutic cancer vaccines have also been developed in recent years in an attempt to boost the immune system to fight off infections or, like other forms of immunotherapy, attempts to spark an immune response to fight the cancer cells. The most well-known types of these vaccines are meant to prevent the HPV virus, which has been linked to several types of cancer, such as cervical and throat cancers. In most cases, however, the drugs have not been approved, although several cancer vaccines are currently being studied in clinical trials. The main drawback of these types of vaccines is that unlike regular vaccines, which train the body to attack viruses by using weakened versions of them, therapeutic cancer vaccines attempt to encourage the body’s immune system to attack a disease that’s already in the body. Lung cancer describes many different types of cancer that start in the lung or related structures. There are two main types of lung cancer: non-small cell (NSCLC) and small cell lung cancer (SCLC). Currently, immune checkpoint inhibitors are available for a subset of advanced-stage NSCLC cancer patients. For those NSCLC patients whose tumors produce high amounts of PD-L1 protein, pembrolizumab, an immunotherapy drug federally approved to treat melanoma and non-small cell lung cancer, is available both in the first-line setting, as well as for those patients who have progressed on chemotherapy. A combination of chemotherapy and pembrolizumab has been shown to work in adenocarcinoma (a subtype of NSCLC) patients whose tumors don’t make PD-L1 protein. Two other drugs, nivolumab and atezolizumab, are available for advanced-stage NSCLC patients in the second-line setting, irrespective of how much PD-L1 protein is made by their tumors. Currently, immunotherapy either as monotherapy or in combination, are ongoing in both NSCLC and SCLC. Readout of these trials will determine standard of care of advanced-stage lung cancer patients. For those battling mesothelioma, a rare cancer often found in the lining of the lung and directly linked to asbestos exposure, immunotherapy could be a new tool patients can use to fight their cancer and extend their lives. Currently, immunotherapy for mesothelioma is showing promise in early clinical trials, namely with pembrolizumab. If the trials continue to present promising results, the treatment could eventually be FDA-approved for mesothelioma, giving doctors and patients an opportunity to more effectively target and treat this aggressive disease. Clinical trials are paramount to furthering our knowledge and generating the best results for current patients and those who may be at risk of developing cancer in the coming years. The advent of the National Cancer Moonshot has streamlined the clinical trial process, which according to the National Cancer Institute has drawn in about 5 percent of cancer patients into trials each year. By making it easier to find and join these important trials, hopefully more patients will get involved and eventually send the valuable information they provide as feedback to their doctors and medical researchers, which ultimately benefits current and future patients. Mesothelioma is only one cancer benefiting from more access to clinical trials, but the overall development of immunotherapy is giving the medical community hope for an eventual cure by better harnessing the body’s own defenses. While immunotherapy is currently being used as both a stand-alone treatment and as part of a combination treatment method with surgery, radiation and/or chemotherapy, one thought is that one day it could replace traditional methods entirely. With that said, we must move along with cautious optimism—there are still many unknowns and a long road of research ahead. Some cancers and even specific patients have not responded as well to current immunotherapy treatment methods. Researchers are hoping to discover more prognostic biomarkers that will better predict which patients will respond well to the treatment based on their cancer type and own gene set. There is still much research to do on improving side effects of immunotherapy as well, which have many factors that affect severity including the patient's health and the stage and type of cancer. As more studies are conducted and research is completed, scientists and researchers hope immunotherapy becomes even more effective at treating not only lung cancer and mesothelioma, but also patients across all cancers. Immunotherapy isn’t a miracle cure for cancers, but it’s quickly becoming a valuable tool doctors and patients can use to extend their lives and raise their quality of life. Immunotherapy as we know it is still in its infancy, but has quickly become a shining star in the medical world. Patients are already reaping some of the benefits this type of treatment provides, and for those in clinical trials, the studies are offering them something intangible: hope. That’s something everyone can use, especially during such a trying and difficult time.
×